AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9165360 — intervention group
Group type: COMPARATOR
Intervention: Collagen coated Dacron graft
Number of subjects: 14
Study 7970842 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (10 mg p.o. daily for 7 days pre-operatively)
Number of subjects: 0
Study 7970842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3315282 — intervention group
Group type: EXPERIMENTAL
Intervention: (2"R)-4'-O-tetrahydropyranyladriamycin (THP) 10-55 mg/m2 administered by i.v. bolus injection daily for acute leukemia
Number of subjects: 84
Study 3315282 — intervention group
Group type: EXPERIMENTAL
Intervention: (2"R)-4'-O-tetrahydropyranyladriamycin (THP) administered according to three different schedules for malignant lymphoma: daily, weekly or once every 3-4 weeks
Number of subjects: 84
Study 3315282 — intervention group
Group type: EXPERIMENTAL
Intervention: (2"R)-4'-O-tetrahydropyranyladriamycin (THP)
Number of subjects: 84
Study 29228206 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment group (n = 33)
Number of subjects: 67
Study 29228206 — intervention group
Group type: COMPARATOR
Intervention: Late treatment group (n = 34)
Number of subjects: 67
Study 27927951 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg S44819
Number of subjects: 18
Study 27927951 — intervention group
Group type: COMPARATOR
Intervention: 50 mg S44819
Number of subjects: 18
Study 27927951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 24656054 — intervention group
Group type: EXPERIMENTAL
Intervention: CRAFT-T
Number of subjects: 52
Study 24656054 — intervention group
Group type: EXPERIMENTAL
Intervention: CRAFT-T (when CSO was parental family)
Number of subjects: 52
Study 24656054 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 52
Study 21887710 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (1,500 Units, 2,500 Units, or 3,500 Units)
Number of subjects: 54
Study 21887710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 21109115 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker treatment initiated >1 to 4 weeks before surgery
Number of subjects: 940
Study 21109115 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker treatment initiated >4 weeks before surgery
Number of subjects: 940
Study 21109115 — intervention group
Group type: COMPARATOR
Intervention: β-blocker treatment initiated <1 week before surgery
Number of subjects: 940
Study 17511802 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy every 4 weeks (cisplatin-paclitaxel or carboplatin-paclitaxel)
Number of subjects: 171
Study 17511802 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy every 3 weeks (cisplatin-paclitaxel or carboplatin-paclitaxel)
Number of subjects: 171
Study 17511802 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-stage disease (chemotherapy every 4 weeks)
Number of subjects: 171
Study 15910869 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10mg
Number of subjects: 324
Study 12714865 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril 20 mg o.d.
Number of subjects: 27
Study 12714865 — intervention group
Group type: COMPARATOR
Intervention: losartan 50 mg o.d.
Number of subjects: 27
Study 12714865 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril 20 mg o.d. (responders only)
Number of subjects: 27
Study 12714865 — intervention group
Group type: COMPARATOR
Intervention: losartan 50 mg o.d. (responders only)
Number of subjects: 27
Study 11127443 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 41
Study 11127443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 8652784 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent control system for insulin dosage recommendations
Number of subjects: 42
Study 8652784 — intervention group
Group type: COMPARATOR
Intervention: Diabetes specialists' recommendations
Number of subjects: 42
Study 1294382 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients
Number of subjects: 152
Study 1294382 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 152
Study 1294382 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients (women)
Number of subjects: 152
Study 1294382 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients (men)
Number of subjects: 152
Study 6238315 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg administered intravenously
Number of subjects: 62
Study 6238315 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen 100 mg associated with noramidopyrine
Number of subjects: 62
Study 30898098 — intervention group
Group type: EXPERIMENTAL
Intervention: Second look diagnostic laparoscopy (DLS)
Number of subjects: 0
Study 30898098 — intervention group
Group type: EXPERIMENTAL
Intervention: Third look DLS after negative second look DLS
Number of subjects: 0
Study 30898098 — intervention group
Group type: COMPARATOR
Intervention: Routine follow-up including 18 months abdominal CT
Number of subjects: 0
Study 28171855 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose group (n = 98)
Number of subjects: 163
Study 28171855 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose group (n = 65)
Number of subjects: 163
Study 28171855 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 163
Study 26048730 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA 500 mg intra-articular injection
Number of subjects: 60
Study 26048730 — intervention group
Group type: COMPARATOR
Intervention: Saline intra-articular injection (control)
Number of subjects: 60
Study 23740284 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (5 mcg/kg/min fixed-dose)
Number of subjects: 20
Study 21716593 — intervention group
Group type: EXPERIMENTAL
Intervention: D-003 (10 mg/day)
Number of subjects: 83
Study 21716593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 19347740 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 82
Study 16443054 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.3%
Number of subjects: 653
Study 16443054 — intervention group
Group type: COMPARATOR
Intervention: Adapalene gel 0.1%
Number of subjects: 653
Study 16443054 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 653
Study 12093655 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical IOP-lowering treatment (mainly beta-blockers)
Number of subjects: 2609
Study 12093655 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical IOP-lowering treatment (n = 33)
Number of subjects: 2609
Study 12093655 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated persons with open-angle glaucoma
Number of subjects: 2609
Study 12093655 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated persons without open-angle glaucoma
Number of subjects: 2609
Study 12093655 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly detected (untreated) glaucoma at baseline
Number of subjects: 2609
Study 10362413 — intervention group
Group type: EXPERIMENTAL
Intervention: 546C88 at 1 mg/kg/hr
Number of subjects: 32
Study 10362413 — intervention group
Group type: EXPERIMENTAL
Intervention: 546C88 at 2.5 mg/kg/hr
Number of subjects: 32
Study 10362413 — intervention group
Group type: EXPERIMENTAL
Intervention: 546C88 at 5 mg/kg/hr
Number of subjects: 32
Study 10362413 — intervention group
Group type: EXPERIMENTAL
Intervention: 546C88 at 10 mg/kg/hr
Number of subjects: 32
Study 10362413 — intervention group
Group type: EXPERIMENTAL
Intervention: 546C88 at 20 mg/kg/hr
Number of subjects: 32
Study 8750372 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg alone
Number of subjects: 12
Study 8750372 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg alone
Number of subjects: 12
Study 8750372 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of losartan 50 mg and hydrochlorothiazide 12.5 mg
Number of subjects: 12
Study 8750372 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 12.5 mg with losartan 50 mg
Number of subjects: 12
Study 2053226 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg of norfenefrine
Number of subjects: 6
Study 2053226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6445254 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal methods (several androgen/gestagen combinations and cyproterone acetate)
Number of subjects: 0
Study 6445254 — intervention group
Group type: COMPARATOR
Intervention: Other male methods known or experienced by users
Number of subjects: 0
Study 6365516 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-based formula supplement providing 800 kcal and 40 g protein daily
Number of subjects: 0
Study 6365516 — intervention group
Group type: COMPARATOR
Intervention: Placebo providing less than 40 kcal per diem
Number of subjects: 0
Study 6365516 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-based formula supplement
Number of subjects: 0
Study 30711327 — intervention group
Group type: EXPERIMENTAL
Intervention: Buzzy
Number of subjects: 195
Study 30711327 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble-blowing
Number of subjects: 195
Study 30711327 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet lidokaine
Number of subjects: 195
Study 30711327 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation aromatherapy with lavender essence
Number of subjects: 195
Study 30711327 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 195
Study 30211823 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous dupilumab 300 mg once weekly (qw)
Number of subjects: 0
Study 30211823 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous dupilumab 300 mg every 2 weeks (q2w)
Number of subjects: 0
Study 30211823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27767433 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (n=15); treatment for 30 days, once weekly for 5 sessions.
Number of subjects: 47
Study 27767433 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen (4.4 mg/kg, PO, q 24 h; n=16); treatment for 30 days.
Number of subjects: 47
Study 27767433 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose capsules, 1 mg/kg, PO, q 24 h; n=16); treatment for 30 days.
Number of subjects: 47
Study 24072404 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-revision surgery patients (N=137)
Number of subjects: 248
Study 24072404 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant removal patients (N=38)
Number of subjects: 248
Study 24072404 — intervention group
Group type: EXPERIMENTAL
Intervention: Revision arthroplasty patients (N=67)
Number of subjects: 248
Study 22172243 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 984
Study 22172243 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline GSM
Number of subjects: 984
Study 22172243 — intervention group
Group type: EXPERIMENTAL
Intervention: Common CIMT
Number of subjects: 984
Study 20930165 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment (multicomponent treatment including aspirin)
Number of subjects: 433
Study 20930165 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 433
Study 20930165 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aspirin treatment)
Number of subjects: 433
Study 18586898 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 40
Study 18586898 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 40
Study 16103773 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVNET 012 (nevirapine)
Number of subjects: 76
Study 16103773 — intervention group
Group type: COMPARATOR
Intervention: Thai-CDC (zidovudine)
Number of subjects: 76
Study 14689885 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter depth of 2 cm and infused semen volume of 0.3 ml
Number of subjects: 330
Study 14689885 — intervention group
Group type: COMPARATOR
Intervention: Catheter depth of 1 cm and infused semen volume of 0.5 ml
Number of subjects: 330
Study 14689885 — intervention group
Group type: COMPARATOR
Intervention: Catheter depth of 1 cm and infused semen volume of 0.3 ml
Number of subjects: 330
Study 14689885 — intervention group
Group type: COMPARATOR
Intervention: Catheter depth of 2 cm and infused semen volume of 0.5 ml
Number of subjects: 330
Study 14689885 — intervention group
Group type: COMPARATOR
Intervention: Catheter depth of 3 cm and infused semen volume of 0.5 ml
Number of subjects: 330
Study 14689885 — intervention group
Group type: COMPARATOR
Intervention: Catheter depth of 3 cm and infused semen volume of 0.3 ml
Number of subjects: 330
Study 10494584 — intervention group
Group type: COMPARATOR
Intervention: Intravenous nicotine (0, 3.5, 7, 14, and 28 micrograms/kg)
Number of subjects: 14
Study 8671479 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterosalpingo-contrast sonography
Number of subjects: 26
Study 8671479 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographically controlled selective tubal catheterization (STC)
Number of subjects: 26
Study 8671479 — intervention group
Group type: COMPARATOR
Intervention: Hysterosalpingo-contrast sonography followed by STC
Number of subjects: 26
Study 8671479 — intervention group
Group type: COMPARATOR
Intervention: STC followed by hysterosalpingo-contrast sonography
Number of subjects: 26
Study 1816570 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.125, 0.25 and 0.5 mg/70 kg of body weight)
Number of subjects: 0
Study 1816570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6752963 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg diazepam suppositories
Number of subjects: 24
Study 6752963 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam suppositories
Number of subjects: 24
Study 31917849 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast scanning mode (energy level of 110 nJ, spot distance of 4.5 mm)
Number of subjects: 39
Study 31917849 — intervention group
Group type: COMPARATOR
Intervention: Standard scanning mode (energy level of 105 nJ, spot distance of 3 mm)
Number of subjects: 39
Study 30783735 — intervention group
Group type: EXPERIMENTAL
Intervention: EH15.5%
Number of subjects: 10
Study 30783735 — intervention group
Group type: EXPERIMENTAL
Intervention: EH13.5%
Number of subjects: 10
Study 30783735 — intervention group
Group type: COMPARATOR
Intervention: EN
Number of subjects: 10
Study 29609240 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly population surveyed
Number of subjects: 5376
Study 29609240 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly females
Number of subjects: 5376
Study 29609240 — intervention group
Group type: COMPARATOR
Intervention: Elderly males
Number of subjects: 5376
Study 29609240 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban residents
Number of subjects: 5376
Study 29609240 — intervention group
Group type: COMPARATOR
Intervention: Rural residents
Number of subjects: 5376
Study 29609240 — intervention group
Group type: EXPERIMENTAL
Intervention: Southern area residents
Number of subjects: 5376
Study 29609240 — intervention group
Group type: COMPARATOR
Intervention: Northern area residents
Number of subjects: 5376
Study 29609240 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 60 years
Number of subjects: 5376
Study 29609240 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 65 years
Number of subjects: 5376
Study 29609240 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 70 years
Number of subjects: 5376
Study 29609240 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 75 years
Number of subjects: 5376
Study 29609240 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 80 years
Number of subjects: 5376
Study 27607363 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tacrolimus
Number of subjects: 0
Study 27607363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24493848 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual fear conditioning and extinction manipulation
Number of subjects: 0
Study 22704391 — intervention group
Group type: EXPERIMENTAL
Intervention: eCG (50 IU/kg im) followed by hCG (500 IU im)
Number of subjects: 25
Study 22704391 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 mL saline solution im)
Number of subjects: 25
Study 20199535 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional stylet
Number of subjects: 10
Study 20199535 — intervention group
Group type: EXPERIMENTAL
Intervention: Hockey-stick stylet
Number of subjects: 10
Study 20199535 — intervention group
Group type: COMPARATOR
Intervention: No stylet
Number of subjects: 10
Study 20199535 — intervention group
Group type: COMPARATOR
Intervention: Styletted tracheal tube
Number of subjects: 10
Study 17379432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cevimeline 30 mg three times daily (with possible escalation to 45 mg)
Number of subjects: 570
Study 17379432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 570
Study 17379432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cevimeline 30-45 mg three times daily
Number of subjects: 570
Study 16274375 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined report intervention (6 physicians and 198 patients received reports and education)
Number of subjects: 665
Study 16274375 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient report intervention (245 patients received reports and education without physician reports)
Number of subjects: 665
Study 16274375 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 665
Study 12209482 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention
Number of subjects: 211
Study 12209482 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 211
Study 10206288 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional polynomials for prognostic modeling
Number of subjects: 686
Study 10206288 — intervention group
Group type: COMPARATOR
Intervention: Traditional approaches using categorized variables or straight line relationships
Number of subjects: 686
Study 7754988 — intervention group
Group type: EXPERIMENTAL
Intervention: Cretan Mediterranean diet
Number of subjects: 605
Study 7754988 — intervention group
Group type: COMPARATOR
Intervention: Usual prescribed diet
Number of subjects: 605
Study 2268862 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 50 mg
Number of subjects: 63
Study 2268862 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 75 mg
Number of subjects: 63
Study 2268862 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg
Number of subjects: 63
Study 2268862 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg
Number of subjects: 63
Study 2268862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 7005653 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentrifrice containing 0.25% fluorine
Number of subjects: 42
Study 7005653 — intervention group
Group type: COMPARATOR
Intervention: Similar toothpaste containing fluorine
Number of subjects: 42
Study 28976249 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait training with auditory feedback caused by active weight bearing on the paralyzed side (experimental group)
Number of subjects: 24
Study 28976249 — intervention group
Group type: COMPARATOR
Intervention: General gait intervention over the ground (control group)
Number of subjects: 24
Study 27256080 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii group (WG)
Number of subjects: 19
Study 27256080 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 19
Study 25992746 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed course of antibiotics for 4±1 calendar days
Number of subjects: 518
Study 25992746 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics until 2 days after resolution of fever, leukocytosis, and ileus, maximum of 10 days
Number of subjects: 518
Study 22967857 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 90
Study 22967857 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss (BWL)
Number of subjects: 90
Study 22967857 — intervention group
Group type: COMPARATOR
Intervention: Control Group (non-overvaluation)
Number of subjects: 90
Study 21593290 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle weight loss (LWL) intervention through a diabetes education program (DEP) delivered by community health workers (CHWs)
Number of subjects: 301
Study 21593290 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual-care condition
Number of subjects: 301
Study 19696287 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast material of 300 mg I/mL (Protocol A)
Number of subjects: 36
Study 19696287 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast material of 370 mg I/mL (Protocol B)
Number of subjects: 36
Study 19696287 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast material of 370 mg I/mL plus saline flush (Protocol C)
Number of subjects: 36
Study 16809571 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% human albumin (ALB) infusion, doses ranging from 0.34 to 2.05 g/kg, administered over 2 hours within 16 hours of stroke onset
Number of subjects: 82
Study 16809571 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care intravenous tissue plasminogen activator (tPA)
Number of subjects: 82
Study 12777860 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD25 monoclonal antibody (daclizumab)
Number of subjects: 0
Study 12777860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10966537 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical data from the Cardiac Care Network of Ontario
Number of subjects: 9
Study 10966537 — intervention group
Group type: COMPARATOR
Intervention: Administrative data from the Canadian Institute for Health Information
Number of subjects: 9
Study 10966537 — intervention group
Group type: EXPERIMENTAL
Intervention: Both data sources
Number of subjects: 9
Study 8603263 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body hyperthermia at 40 degrees C
Number of subjects: 6
Study 8603263 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body hyperthermia at 42 degrees C
Number of subjects: 6
Study 8603263 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 6